Milestone Pharmaceuticals (MIST) Price & Analysis

Compare

624 Followers

MIST Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.63 - $2.75

Previous CloseN/A

Volume143.50K

Average Volume (3M)2.08M

Market Cap

$130.84M

Enterprise Value$52.66M

Total Cash (Recent Filing)$55.96M

Total Debt (Recent Filing)$55.59M

Price to Earnings (P/E)―

Beta2.13

Next Earnings

Nov 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding84,964,270

10 Day Avg. Volume886,842

30 Day Avg. Volume2,080,976

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.40

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.03K

Enterprise Value/Ebitda-1.06

Forecast

1Y Price Target

$4.50

Price Target Upside202.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceIf etripamil is approved, MIST will receive $75M in net proceeds from their RTW agreement.

Regulatory ApprovalsThe FDA's acceptance of Milestone Pharmaceuticals' resubmission for Cardamyst is seen as a significant positive, with the potential for approval and commercial success considered underappreciated.

Bears Say

Operational ChallengesLaunch prospects are also constrained by limited capital.

Regulatory ChallengesCardamyst has faced a longer regulatory timeline with prior Complete Response Letters and Refuse-to-file actions from the FDA, creating uncertainty about its approvability.

Milestone Pharmaceuticals News

Why Is Milestone Pharmaceuticals Stock (MIST) Down 30% Today?

Milestone Pharmaceuticals stock was down on Friday after the company revealed plans for a public offering. ...

27d ago

MIST

Milestone prices $52.5M common shares offering at $1.50 per share

Milestone Pharmaceuticals (MIST) announced the pricing of its previously announced underwritten public offering of (i) 31.5M of its...

28d ago

MIST

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Investors will want to catch up on all of the hottest stock market news for Friday before signing off for the week. ...

28d ago

AMD

Milestone Pharmaceuticals commences underwritten public offering

Milestone Pharmaceuticals (MIST) has commenced an underwritten public offering of its common shares, accompanying Series A warrants to...

28d ago

MIST

Milestone announces FDA acceptance of response to CARDAMYST CRL

Milestone Pharmaceuticals (MIST) announced that the U.S. Food and Drug Administration has accepted for review Milestone’s response to...

28d ago

MIST

Milestone Pharmaceuticals’ Cardamyst NDA Resubmission Boosts Buy Rating Amid FDA Progress

In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Milestone Pharmaceuticals, with...

24d ago

MIST

Milestone Pharmaceuticals Announces Public Offering for $48.7M

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On July 11, 2025, Milestone Pharmaceuticals announced an underwritten...

25d ago

MIST

Milestone Pharmaceuticals Amends Royalty Agreement with RTW

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On July 10, 2025, Milestone Pharmaceuticals amended its Royalty...

28d ago

MIST

Milestone Pharmaceuticals’ Cardamyst Resubmission Boosts Buy Rating Amid Positive FDA Feedback and Market Potential

In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Milestone Pharmaceuticals (MIST...

2M ago

MIST

Milestone Pharmaceuticals Submits Response to FDA for CARDAMYST

An update from Milestone Pharmaceuticals ( ($MIST) ) is now available. On June 16, 2025, Milestone Pharmaceuticals announced...

2M ago

MIST

Milestone Pharmaceuticals sumbits CRL response for CARDAMYST nasal spray

Milestone announced submission of its response to the U.S. Food and Drug Administration’s Complete Response Letter regarding its...

2M ago

MIST

Milestone Pharmaceuticals Holds Annual Shareholder Meeting

Milestone Pharmaceuticals ( ($MIST) ) has shared an update. At the Annual Meeting, Milestone Pharmaceuticals‘ shareholders voted on...

2M ago

MIST

Milestone Pharmaceuticals’ Path to Approval: Addressing CMC Issues for Cardamyst’s Market Potential

Brandon Folkes, an analyst from H.C. Wainwright, has initiated a new Buy rating on Milestone Pharmaceuticals (MIST). Brandon...

2M ago

MIST

Milestone Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes assumed coverage of Milestone Pharmaceuticals (MIST) with a Buy rating and $5 price...

2M ago

MIST

MIST FAQ

What was Milestone Pharmaceuticals’s price range in the past 12 months?

Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $2.75 in the past 12 months.

What is Milestone Pharmaceuticals’s market cap?

Milestone Pharmaceuticals’s market cap is $130.84M.

When is Milestone Pharmaceuticals’s upcoming earnings report date?

Milestone Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.

How were Milestone Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Milestone Pharmaceuticals overvalued?

According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Milestone Pharmaceuticals pay dividends?

Milestone Pharmaceuticals does not currently pay dividends.

What is Milestone Pharmaceuticals’s EPS estimate?

Milestone Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals has 84,964,270 shares outstanding.

What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Milestone Pharmaceuticals?

Currently, no hedge funds are holding shares in MIST

Milestone Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-307.27%

Trailing 12-Months

Asset Growth

-35.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals (MIST) Earnings & Revenues

Historic Earnings Reports

MIST Stock 12 Month Forecast

Average Price Target

$4.50

▲(202.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.12,2.36,2.6,2.84,3.08,3.3200000000000003,3.56,3.8,4.04,4.28,4.52,4.76,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.0815384615384613,2.283076923076923,2.4846153846153847,2.686153846153846,2.8876923076923076,3.0892307692307694,3.290769230769231,3.4923076923076923,3.693846153846154,3.8953846153846152,4.096923076923077,4.298461538461538,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.043076923076923,2.206153846153846,2.3692307692307693,2.5323076923076924,2.6953846153846155,2.8584615384615386,3.0215384615384613,3.184615384615385,3.3476923076923075,3.510769230769231,3.6738461538461538,3.836923076923077,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >